Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: Intracrinology

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 8, 1997, Pages 2403-2409

  Labrie, Fernand ^a   Bélanger, Alain ^b   Cusan, Lionel ^b   Candas, Bernard ^b  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIOL; ANDROSTENEDIONE; ANDROSTERONE; ESTRADIOL; ESTROGEN; ESTRONE; HYDROCORTISONE; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; ARTICLE; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; FEMALE; FIRST PASS EFFECT; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TOPICAL DRUG ADMINISTRATION;

EID: 0030748614     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.8.4161     Document Type: Article

References (46)

1. Butenandt A, Tscherning K. 1934 Uber Androsteron, Krystallisiertes mannliches Sexualhormon. I. Bolierung und Reindarstellung aus Munnerharn. Z Physiol Chem. 229:167-184.
2. Munson PL, Gallagher TF, Koch FC. 1944 Isolation of dehydroisoandrosterone sulfate from normal male urine. J Biol Chem. 152:67-77.
3. Migeon CJ, Plager JE. 1954 Identification and isolation of dehydroepiandrosterone from peripheral human plasma. J Biol Chem. 209:767-772.
4. Bélanger A, Candas B, Dupont A, et al. 1994 Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab. 79:1086-1090.
5. Labrie F, Dupont A, Bélanger A. 1985 Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: J. B. Lippincott: pp 193-217.
6. Labrie F. 1991 Intracrinology. Mol Cell Endocrinol. 78:C113-C118.
7. Bélanger B, Bélanger A, Labrie F, et al. 1989 Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem. 32:695-698.
8. Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C. 1995 DHEA and peripheral androgen and estrogen formation: Intracrinology. Ann NY Acad Sci. 774:16-28.
9. Labrie F, Luu-The V, Lin SX, et al. 1997 The key role of 17β-HSDs in sex steroid biology. Steroids. 62:148-158.
10. Labrie F, Simard J, Luu-The V, et al. 1996 The 3β-hydroxysteroid dehydrogenase/isomerase gene family: lessons from type II 3β-HSD congenital deficiency. In: Hansson, V, Levy, FO, Taskén, K (eds) Signal Transduction in Testicular Cells. Ernst Schering Research Foundation Workshop. Berlin: Springer-Verlag, vol 2[Suppl]:185-218.
11. Labrie C, Bélanger A, Labrie F. 1988 Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology. 123:1412-1417.
12. Andersson S, Russel DW. 1990 Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA. 87:3640-3644.
13. Andersson S, Bergman DM, Jenkins EP, Russel DW. 1991 Deletion of steroid 5α-reductase 2 gene in male pseudophermaphroditism. Nature. 354:159-161.
14. Bernier F, Leblanc G, Labrie F, Luu-The V. 1994 Structure of human estrogen and aryl sulfotransferase gene. Two mRNA species issued from a single gene. J Biol Chem. 269:28200-28205.
15. Bernier F, Lopez-Solache I, Labrie F, Luu-The V. 1994 Cloning and expression of cDNA encoding human placental estrogen sulfotransferase. Mol Cell Endocrinol. 99:R11-R15.
16. Luu-The V, Dufort I, Paquet N, Reimnitz G, Labrie F. 1995 Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene. DNA Cell Biol. 14:511-518.
17. Rhéaume E, Simard J, Morel Y, et al. 1992 Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase deficiency. Nature Genetics. 1:239-245.
18. Labrie F, Sugimoto Y, Luu-The V, et al. 1992 Structure of human type II 5α-reductase. Endocrinology. 131:1571-1573.
19. Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G. 1992 Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues. J Steroid Biochem Mol Biol. 43:805-826.
20. Luu-The V, Zhang Y, Poirier D, Labrie F. 1995 Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation-reduction and inhibition. J Steroid Biochem Mol Biol. 55:581-587.
21. Labrie Y, Durocher F, Lachance Y, et al. 1995 The human type II 17β-hydroxysteroid dehydrogenase gene encodes two alternatively-spliced messenger RNA species. DNA Cell Biol. 14:849-861.
22. Vermeulen A, Deslypene JP, Schelthout W, Verdonck L, Rubens R. 1982 Adrenocortical function in old age: response to acute adrenocorticotropin stimulation. J Clin Endocrinol Metab. 54:187-191.
23. Vermeulen A, Verdonck L. 1976 Radioimmunoassays of 17β-hydroxy-5α-androstan-3-one, 4-androstene-3,17-dione, dehydroepiandrosterone, 17β-hydroxyprogesterone and progesterone and its application to human male plasma. J Steroid Biochem. 7:1-10.
24. Orentreich N, Brind JL, Rizer RL, Vogelman JH. 1984 Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 59:551-555.
25. Migeon CJ, Keller AR, Lawrence B, Shepart II TH. 1957 Dehydroepiandrosterone and androsterone levels in human placenta. Effect of age and sex: day-to-day and diurnal variations. J Clin Endocrinol Metab. 17:1051-1062.
26. Schriock ED, Buffington CK, Hubert GD, et al. 1988 Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab. 66:1329-1331.
27. Coleman DL, Leiter EH, Schwizer RW. 1982 Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes. 31:830-833.
28. Nestler JE, Barlascini CO, Clore JN, Blackard WG. 1988 Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 66:57-61.
29. MacEwen EG, Kurzman ID. 1991 Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). J Nutr. 121:S51-S55.
30. Zumoff B, Levin J, Rosenfeld RS, et al. 1981 Abnormal 24-hr mean plasma concentrations of dehydroepiandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res. 41:3360-3363.
31. Stahl F, Schnorr D, Pilz C, Dorner G. 1992 Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol. 99:68-70.
32. Schwartz AG, Pashko L, Whitcomb JM. 1986 Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol. 14:357-362.
33. Gordon GB, Shantz LM, Talalay P. 1987 Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul. 26:355-382.
34. Li S, Yan X, Bélanger A, Labrie F. 1993 Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat. 29:203-217.
35. Casson PR, Andersen RN, Herrod HG, et al. 1993 Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol. 169:1536-1539.
36. Mortola JF, Yen SS. 1990 The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab. 71:1360-1367.
37. Morales AJ, Nolan JJ, Nelson JC, Yen SS. 1994 Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab. 78:1360-1367.
38. Diamond P, Cusan L, Gomez JL, Bélanger A, Labrie F. 1996 Metabolic effects of 12-month percutaneous DHEA replacement therapy in postmenopausal women. J Endocrinol. 150:S43-S50.
39. Labrie C, Flamand M, Bélanger A, Labrie F. 1996 High bioavailability of DHEA administered percutaneously in the rat. J Endocrinol. 150:S107-S118.
40. Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L. 1988 Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma. Clin Invest Med. 11:321-326.
41. Bélanger A, Caron S, Picard V. 1980 Simultaneous radioimmunoassay of progestins, androgens, and estrogens in adult rat testis. J Steroid Biochem. 13:185-190.
42. Bélanger A, Labrie F, Angeli A. 1990 Unconjugated and glucuronide steroid levels in human breast cyst fluid. Ann NY Acad Sci. 586:93-100.
43. Rodbard D. 1974 Apparent positive cooperative effect in cyclic AMP and corticosteroid production by isolated adrenal cells in response to ACTH analogs. Endocrinology. 94:1427-1437.
44. Kramer CY. 1956 Extension of multiple range tests to group means with unique numbers of replications. Biometrics. 12:307-310.
45. Labrie F, Bélanger A, Dupont A, et al. 1993 Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med. 16:475-492.
46. Bélanger A, Brochu M, Cliche J. 1986 Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer. J Clin Endocrinol Metab. 62:812-815.